

SUPPLEMENTARY MATERIAL 1

The global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study

Jingru Tian^{1,2,3}, Dingyao Zhang^{4,5}, Xu Yao¹, Yaqing Huang⁶, and Qianjin Lu^{1,2,3*}

¹Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China

²Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China

³Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China

⁴Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, USA

⁵Program in Computational Biology and Bioinformatics, Yale University, New Haven, USA

⁶Department of Pathology, Yale University, New Haven, USA

* Correspondence should be addressed to:

Qianjin Lu, 12 Jiangwangmiao Street, Xuanwu, Nanjing, Jiangsu, China 210042.

Telephone: 025-85478999; Fax: 025-85414477;

Email: qianlu5860@pumcderm.cams.cn

Appendices index

Appendix 1 Detailed methods	3
Appendix 2 Search strategy	5
Appendix 3 Literature search and selection.....	7
Appendix 4 Characteristics of studies reporting on incidence of AD.....	8
Appendix 5 Quality assessment of studies using the AXIS tool	50
Appendix 6 Countries and territories in analysis regions	55
Appendix 7 Statistical methods for incidence and prevalence calculation.....	57
Appendix 8 Trace plots for covariates in the Bayesian multilevel model	59
Appendix 9 Subgroup analysis of classification criteria and diagnostic method.....	61
Appendix 10 Validate the accuracy of the Bayesian model	64

Definitions and analytic framework

We performed a systematic review and meta-analysis of the incidence and prevalence of systemic lupus erythematosus (SLE). Incidence data were summarized descriptively, whereas using prevalence data we generated global, regional, and country-specific estimates of the prevalence of the disease for 2022.

The study was carried out according to the following main steps:

- Descriptive summary of incidence and prevalence data.
- Development of a hierarchical model to estimate the global, regional, and country-specific prevalence and incidence of SLE.

Appendix 1 Detailed methods

a. Search strategy

Two investigators (JR.T and DY.Z) systematically searched four electronic (MEDLINE, EMBASE, Web of Science, and China National Knowledge Infrastructure) from January 1, 1992 to May 7, 2022, appraised studies on eligibility, and extracted data independently. Data extracted from each study included citation data (title of the study, authors, publication year); study period; study population (country, ethnicity, age group, sex); study methods (diagnostic method (dermatologists, physician or self-reported); outcome measure (incidence and/or prevalence); type of prevalence (point, period or life-time); and findings (number of people with SLE, values of the prevalence and/or incidence reported and their 95% confidence intervals (CIs)). Discrepancies were discussed and agreed by consensus.

The MeSH and keyword search terms associated with SLE were used in each database. In order not to miss out on potentially useful articles, references cited in relevant reviews were also searched manually.

b. Study selection

We evaluated published articles at the title or abstract level, with divergences resolved after consensus by two independent investigators. If potentially relevant, we evaluated them as complete reports according to prespecified selection criteria. Studies from any country in the world and/or in any language were included if they met

the inclusion criteria. No restriction on the type of population regarding age, sex, and severity of SLE or regarding type of diagnosis (self-reported, physician diagnosis or dermatologist diagnosis) was applied. We excluded studies which are: 1) non-human studies; 2) not cross-sectional surveys or cohorts of representative (general) populations of a country or area of a country; 3) were not carried out on the general population (i.e. people were identified from specific populations such as department of rheumatology or dermatology clinics, or specific subgroups of the population); 4) focused only on comorbidities of SLE; 5) no clear definition of SLE, or combined with other autoimmune diseases. In addition, published articles which are: 1) without full text (i.e. abstracts and conference proceedings) or not reporting original studies (i.e. narrative reviews, meta-analyses, editorials, commentaries, protocols, guidelines, or perspectives); or 2) duplicate reports were also excluded. The search process of literature from published articles were shown below.

c. Quality Assessment

A formal assessment of the quality of the included studies was performed independently by two investigators (JR.T and DY.Z) using the Appraisal tool of Cross-Sectional Studies (AXIS tool). The AXIS tool is a 20-item quality assessment tool designed to assist researchers to critically appraise studies, specifically in the process of conducting systemic reviews. The 20-items cover the following domains: identification of research aims, appropriateness of study design, use of valid measures and statistical analyses and consideration of bias. In the current systematic review, studies were classified as having high, medium, or low risk of bias or unclear according to the overall quality of the methods used and reporting of results in the study. The risk of bias assessment for individual studies was included in Table S8.

Appendix 2 Search strategies

Table S1. The search strategy in PubMed (Medline)

#	Terms	Quotes
4	#1 AND #2 NOT #3	20.188
3	animals [mh] NOT humans [mh]	5.002.462
2	((incidence or incident) OR (exp Incidence/) OR (incidence stud*) OR (cohort stud*) OR (exp Cohort Studies/) OR (exp Follow-Up Studies/) OR (follow-up stud*) OR (prospective stud*) OR (exp Prospective Studies/) OR (longitudinal stud*) OR (exp Longitudinal Studies/) OR ((epidemiol* SLEj stud*)) OR (exp Epidemiologic Studies/) OR (exp Epidemiology/) OR (exp Prevalence/) OR (prevalence stud*) OR (exp Cross-Sectional Studies/) OR (cross-sectional stud*))	5.958.181
1	("Lupus Erythematosus, Systemic"[Mesh] OR Systemic Lupus Erythematosus OR Lupus Erythematosus Disseminatus OR Libman-Sacks Disease OR Disease, Libman-Sacks OR Libman Sacks Disease) OR ("Lupus Nephritis"[Mesh] OR Lupus Glomerulonephritis OR Nephritis, Lupus OR Lupus Nephritides OR Nephritides, Lupus OR Glomerulonephritis, Lupus OR Glomerulonephritides, Lupus OR Lupus Glomerulonephritides) OR (systemic lupus erythematosus))	81.475

Table S2. The search strategy in Embase

#	Terms	Quotes
3	#1 AND #2 AND [humans]/lim	6.044
2	'Incidence'/exp OR 'Cohort Studies'/exp OR 'incidence or incident':ti,ab,kw OR 'incidence stud*':ti,ab,kw OR 'cohort stud*':ti,ab,kw OR 'Follow-Up Studies '/exp OR 'follow-up stud*' OR 'prospective stud*' OR 'Prospective Studies'/exp OR 'longitudinal stud*' OR 'Longitudinal Studies'/exp OR 'epidemiol* SLEj stud*' OR 'Epidemiologic Studies'/exp OR 'Epidemiology'/exp OR 'prevalence or prevalen' OR 'Prevalence'/exp OR 'prevalence stud*' OR 'Cross-Sectional Studies'/exp OR 'cross-sectional stud*' OR 'lupus erythematosus nephritis'/exp OR 'glomerulonephritis lupoid' OR 'lupoid nephritis' OR 'lupus erythematosus nephritis' OR 'lupus glomerulonephritis' OR 'lupus kidney' OR 'lupus nephritis' OR 'lupus nephropathy' OR 'nephritis lupus erythematosus' OR 'nephritis systemic lupus erythematosus' OR 'systemic lupus erythematosis, nephritis') AND [embase]/lim	6.403.284
1		19.482


Table S3. Web of Science search (contain Web of Science Core Collection; MEDLINE; Current Contents Connect; SciELO Citation Index; Data Citation Index; and KCI-Korean Journal Database)

#	Terms	Quotes
1	TS=(incidence OR incident)	1.967.954
2	TS=(incidence study or incidence studies)	1.012.097
3	TS=(cohort study or cohort studies)	981.405
4	TS=(follow-up study or follow-up studies or follow up study or follow up studies)	1.894.102
5	TS=(prospective study or prospective studies)	1.023.716
6	TS=(longitudinal study or longitudinal studies)	505.799
7	TS=(epidemiolo* study or epidemiolo* studies)	2.204.540

8	TS=(epidemiology)	2.734.018
9	TS=(prevalence OR prevalent)	1.679.733
10	TS=(prevalence study or prevalence studies)	1.140.594
11	TS=(cross-sectional study OR cross-sectional studies OR cross sectional study OR cross sectional studies)	712.847
12	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11	7.963.989
13	TS=(lupus erythematosus, systemic)	145.435
14	TS=(lupus nephritis)	26.576
15	TS=(lupus)	199.364
16	TS=(lupus vasculitis)	14.108
17	TS=(lupus erythematosus)	157.590
18	TS=(systemic lupus erythematosus)	2.318
19	TS=(systemic lupus erythematosis)	1.810
20	TS=(systemic lupus erythematosus)	145.435
21	TS=(lupus erythematosus visceralis)	91
22	#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	199.364
23	#22 and #12	37.220

Table S4. The search strategy in China National Knowledge Infrastructure (CNKI)

#	Terms	Quotes
1	Incidence OR epidemiology OR prevalence	499.292
2	Systemic lupus erythematosus	23.061
3	#1 AND #2	191

Appendix 3 Literature search and selection**Figure S1. Literature search and selection from published articles**

Appendix 4 Characteristics of studies reporting on incidence of AD.**Table S5. The Appraisal tool of Cross-Sectional Studies (AXIS tool)**

Question	Yes	No	Don't know/ Comment
Introduction			
1 Were the aims/objectives of the study clear?			
Methods			
2 Was the study design appropriate for the stated aim(s)?			
3 Was the sample size justified?			
4 Was the target/reference population clearly defined? (Is it clear who the research was about?)			
5 Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?			
6 Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation?			
7 Were measures undertaken to address and categorise non-responders?			
8 Were the risk factor and outcome variables measured appropriate to the aims of the study?			
9 Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published previously?			
10 Is it clear what was used to determine statistical significance and/or precision estimates? (e.g. p-values, confidence intervals)			
11 Were the methods (including statistical methods) sufficiently described to enable them to be repeated?			
Results			
12 Were the basic data adequately described?			
13 Does the response rate raise concerns about non-response bias?			
14 If appropriate, was information about non-responders described?			
15 Were the results internally consistent?			
16 Were the results presented for all the analyses described in the methods?			
Discussion			
17 Were the authors' discussions and conclusions justified by the results?			
18 Were the limitations of the study discussed?			
Other			
19 Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?			
20 Was ethical approval or consent of participants attained?			

Table S6. Characteristics of studies reporting on incidence of AD.

No.	Study	Study time	Incidence	Country	Reference
45	Gonzalez Lucero et al., 2020	2005-2012	Incidence (ACR)	Argentina	Gonzalez Lucero L, Barbaglia AL, Bellomio VI, Bertolaccini MC, Machado Escobar MA, Sueldo HR, Yacuzzi MS, Carrizo GA, Robles N, Rengel S, Cristofari A, Leal MO, Vasquez DL, Quinteros A, Seleme G, Molina MJ, Pera OL, Dip R, Olea AC, Torres AY, Espindola Echazu M, Arquez G, Lazaro H, Colombres F, Juarez LA, Romano O, Paz S, Santana M, Galindo L, Lucero E. Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina. <i>Lupus</i> . 2020 Nov;29(13):1815-1820.
98	Scolnik et al., 2014	1998-2009	Incidence (ACR)	Argentina	Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS, Avellaneda NL, Etchepare A, Etchepare P, Plou MS, Soriano ER. Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. <i>Lupus Sci Med</i> . 2014 Jun 5;1(1):e000021.
65	Mackie et al., 2015	2009-2011	Incidence (ACR)	Australia	Mackie FE, Kainer G, Adib N, Boros C, Elliott EJ, Fahy R, Munro J, Murray K, Rosenberg A, Wainstein B, Ziegler JB, Singh-Grewal D. The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit. <i>Lupus</i> . 2015 Jan;24(1):66-73.
111	Anstey et al., 1993	1991	Incidence (ARA)	Australia	Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. <i>Aust N Z J Med</i> . 1993 Dec;23(6):646-51.
42	Flower et al., 2012	2000-2009	Incidence (ACR)	Barbados	Flower C, Hennis AJ, Hambleton IR, Nicholson GD, Liang MH; Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. <i>Arthritis Care Res (Hoboken)</i> . 2012 Aug;64(8):1151-8.
70	Molokhia et al., 2001	2007-2008	Incidence (ACR)	Brazil	Molokhia M, McKeigue PM, Cuadrado M, Hughes G. Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK. <i>Lancet</i> . 2001 May 5;357(9266):1414-5.
87	Vilar et al., 2002	2000	Incidence (ACR)	Brazil	Vilar MJ, Sato EI. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). <i>Lupus</i> . 2002;11(8):528-32.

10	Bernatsky et al., 2007	1994-2003	Incidence	Canada	Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE, Clarke AE. A population-based assessment of systemic lupus erythematosus incidence and prevalence--results and implications of using administrative data for epidemiological studies. <i>Rheumatology (Oxford)</i> . 2007 Dec;46(12):1814-8.
38	Fatoye et al., 2018	2000-2015	Incidence	Canada	Fatoye F, Gebrye T, Svenson LW. Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada. <i>Rheumatol Int</i> . 2018 Sep;38(9):1721-1726.
73	Ng et al., 2013	2001	Incidence	Canada	Ng R, Bernatsky S, Rahme E. Observation period effects on estimation of systemic lupus erythematosus incidence and prevalence in Quebec. <i>J Rheumatol</i> . 2013 Aug;40(8):1334-6.
13	Chiu et al., 2010	2001	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2002	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2003	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2004	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2005	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2006	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2007	Incidence	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
61	Leong et al., 2021	2003	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.

61	Leong et al., 2021	2004	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2005	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2006	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2007	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2008	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2009	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2010	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2011	Incidence	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
91	Yeh et al., 2013	2003	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.

91	Yeh et al., 2013	2004	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.
91	Yeh et al., 2013	2005	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.
91	Yeh et al., 2013	2006	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.
91	Yeh et al., 2013	2007	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.
91	Yeh et al., 2013	2008	Incidence	China	Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. <i>Rheumatol Int.</i> 2013 Jul;33(7):1805-11.
112	Mok et al., 2008	2000	Incidence (ACR)	China	Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. <i>J Rheumatol.</i> 2008 Oct;35(10):1978-82.
112	Mok et al., 2008	2006	Incidence (ACR)	China	Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. <i>J Rheumatol.</i> 2008 Oct;35(10):1978-82.
48	Hermansen et al., 2016	1995-2011	Incidence	Denmark	Hermansen ML, Lindhardsen J, Torp-Pedersen C, Faurschou M, Jacobsen S. Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. <i>J Rheumatol.</i> 2016 Jul;43(7):1335-9.
60	Lastrupup et al., 2009	1995	Incidence (ACR)	Denmark	Lastrupup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.

60	Lastrup et al., 2009	1996	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	1997	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	1998	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	1999	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2000	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2001	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2002	Incidence (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
75	Otsa et al., 2017	2006-2010	Incidence (ACR)	Estonia	Otsa K, Talli S, Harding P, Parsik E, Esko M, Teepera A, Tammaru M. Prevalence and incidence of systemic lupus erythematosus in the adult population of Estonia. <i>Lupus.</i> 2017 Sep;26(10):1115-1120.
37	Elfving et al., 2014	2000-2007	Incidence	Finland	Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O. Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study. <i>Clin Exp Rheumatol.</i> 2014 Nov-Dec;32(6):953-5

37	Elfving et al., 2014	2000-2007	Incidence	Finland	Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O. Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study. <i>Clin Exp Rheumatol.</i> 2014 Nov-Dec;32(6):953-5
6	Arnaud et al., 2014	2010	Incidence	France	Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. <i>Autoimmun Rev.</i> 2014 Nov;13(11):1082-9.
36	Deligny et al., 2002	1990-1999	Incidence (ACR)	France	Deligny C, Thomas L, Dubreuil F, Théodore C, Garsaud AM, Numéric P, Ranlin A, Jean-Baptiste G, Arfi S. Lupus systémique en Martinique: enquête épidémiologique [Systemic lupus erythematosus in Martinique: an epidemiologic study]. <i>Rev Med Interne.</i> 2002 Jan;23(1):21-9.
2	Schwarting et al., 2021	2009	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2010	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2011	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2012	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2013	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany:

					Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2014	Incidence	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther.</i> 2021 Mar;8(1):375-393.
94	Brinks et al., 2016	2002	Incidence	Germany	Brinks R, Hoyer A, Weber S, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M. Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002. <i>Lupus Sci Med.</i> 2016 Nov 25;3(1):e000181.
4	Alamanos et al. 2003	1982-1986	Incidence (ACR)	Greece	Alamanos Y, Voulgari PV, Siozos C, Katsimpi P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. <i>J Rheumatol.</i> 2003 Apr;30(4):731-5.
4	Alamanos et al. 2003	1987-1991	Incidence (ACR)	Greece	Alamanos Y, Voulgari PV, Siozos C, Katsimpi P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. <i>J Rheumatol.</i> 2003 Apr;30(4):731-5.
4	Alamanos et al. 2003	1992-1996	Incidence (ACR)	Greece	Alamanos Y, Voulgari PV, Siozos C, Katsimpi P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. <i>J Rheumatol.</i> 2003 Apr;30(4):731-5.
4	Alamanos et al. 2003	1997-2001	Incidence (ACR)	Greece	Alamanos Y, Voulgari PV, Siozos C, Katsimpi P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. <i>J Rheumatol.</i> 2003 Apr;30(4):731-5.
44	Gergianaki et al., 2017	1999-2013	Incidence (ACR)	Greece	Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spirou G, Bertsias A, Kabouraki E, Tzanakis I, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias GK. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. <i>Ann Rheum Dis.</i> 2017 Dec;76(12):1992-2000.

97	Kedves et al., 2020	2010	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2011	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2012	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2013	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2014	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2015	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2016	Incidence	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.

47	Govoni et al., 2006	2000	Incidence (ACR)	Italy	Govoni M, Castellino G, Bosi S, Napoli N, Trotta F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. <i>Lupus</i> . 2006;15(2):110-3.
47	Govoni et al., 2006	2001	Incidence (ACR)	Italy	Govoni M, Castellino G, Bosi S, Napoli N, Trotta F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. <i>Lupus</i> . 2006;15(2):110-3.
47	Govoni et al., 2006	2002	Incidence (ACR)	Italy	Govoni M, Castellino G, Bosi S, Napoli N, Trotta F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. <i>Lupus</i> . 2006;15(2):110-3.
85	Tsioni et al., 2015	2009-2012	Incidence (ACR)	Italy	Tsioni V, Andreoli L, Meini A, Frassi M, Raffetti E, Airò P, Allegri F, Donato F, Tincani A. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. <i>Clin Exp Rheumatol</i> . 2015 Sep-Oct;33(5):681-7.
54	Iseki et al., 1994	1982-1991	Incidence (ARA)	Japan	Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. <i>Am J Kidney Dis</i> . 1994 Apr;23(4):547-54.
72	Nasonov et al., 2014	2010	Incidence (ACR)	Kazakhstan	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasyliev A, Pereira MH. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus</i> . 2014 Feb;23(2):213-9.
7	Bae et al., 2020	2005	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2006	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.

7	Bae et al., 2020	2007	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2008	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2009	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2010	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2011	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2012	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2013	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2014	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea,

					2005 to 2015: a nationwide population-based study. Korean J Intern Med. 2020 May;35(3):652-661.
7	Bae et al., 2020	2015	Incidence	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. Korean J Intern Med. 2020 May;35(3):652-661.
14	Chung et al., 2021	2011	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2012	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2013	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2014	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2015	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2016	Incidence	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 2021 Apr;30(4):674-679.
58	Kwak et al., 2021	2016-2017	Incidence (ACR)	Korea	Kwak SG, Park SH, Kim JY. Incidence and Prevalence of Juvenile Systemic Lupus Erythematosus in Korea: Data From the 2017 National Health Claims Database. J Rheumatol. 2021 Feb;48(2):258-261.
80	Shim et al., 2014	2008	Incidence (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int. 2014 Jul;34(7):909-17.

80	Shim et al., 2014	2009	Incidence (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
95	Magro et al., 2018	2012-2016	Incidence (SLICC)	Malta	Magro R, Borg AA. Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study. <i>Biomed Res Int.</i> 2018 Sep 30;2018:2385386.
108	Nossent et al., 1992	1980-1989	Incidence (ARA)	Netherlands	Nossent JC. Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation. <i>Ann Rheum Dis.</i> 1992 Nov;51(11):1197-201.
62	Lerang et al., 2012	1999-2008	Incidence (ACR)	Norway	Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT. High incidence and prevalence of systemic lupus erythematosus in Norway. <i>Lupus.</i> 2012 Oct;21(12):1362-9.
102	Nossent et al., 2001	1978-1996	Incidence (ACR)	Norway	Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway. <i>J Rheumatol.</i> 2001 Mar;28(3):539-46.
82	Śliwczyński et al., 2015	2008	Incidence	Poland	Śliwczyński A, Brzozowska M, Iltchev P, Czeleko T, Teter Z, Tłustochowicz W, Marczak M, Tłustochowicz M. Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012. <i>Reumatologia.</i> 2015;53(2):79-86.
82	Śliwczyński et al., 2015	2009	Incidence	Poland	Śliwczyński A, Brzozowska M, Iltchev P, Czeleko T, Teter Z, Tłustochowicz W, Marczak M, Tłustochowicz M. Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012. <i>Reumatologia.</i> 2015;53(2):79-86.
82	Śliwczyński et al., 2015	2010	Incidence	Poland	Śliwczyński A, Brzozowska M, Iltchev P, Czeleko T, Teter Z, Tłustochowicz W, Marczak M, Tłustochowicz M. Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012. <i>Reumatologia.</i> 2015;53(2):79-86.
82	Śliwczyński et al., 2015	2011	Incidence	Poland	Śliwczyński A, Brzozowska M, Iltchev P, Czeleko T, Teter Z, Tłustochowicz W, Marczak M, Tłustochowicz M. Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012. <i>Reumatologia.</i> 2015;53(2):79-86.
82	Śliwczyński et al., 2015	2012	Incidence	Poland	Śliwczyński A, Brzozowska M, Iltchev P, Czeleko T, Teter Z, Tłustochowicz W, Marczak M, Tłustochowicz M. Changes in the morbidity and costs of systemic

					lupus erythematosus in Poland in the years 2008-2012. <i>Reumatologia</i> . 2015;53(2):79-86.
72	Nasonov et al., 2014	2010	Incidence (ACR)	Russia	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasyliev A, Pereira MH. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus</i> . 2014 Feb;23(2):213-9.
5	Alonso et al., 2011	1987-1991	Incidence (ACR)	Spain	Alonso MD, Llorca J, Martinez-Vazquez F, Miranda-Filloy JA, Diaz de Teran T, Dierssen T, Vazquez-Rodriguez TR, Gomez-Acebo I, Blanco R, Gonzalez-Gay MA. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. <i>Medicine (Baltimore)</i> . 2011 Sep;90(5):350-358.
5	Alonso et al., 2011	1992-1996	Incidence (ACR)	Spain	Alonso MD, Llorca J, Martinez-Vazquez F, Miranda-Filloy JA, Diaz de Teran T, Dierssen T, Vazquez-Rodriguez TR, Gomez-Acebo I, Blanco R, Gonzalez-Gay MA. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. <i>Medicine (Baltimore)</i> . 2011 Sep;90(5):350-358.
5	Alonso et al., 2011	1997-2001	Incidence (ACR)	Spain	Alonso MD, Llorca J, Martinez-Vazquez F, Miranda-Filloy JA, Diaz de Teran T, Dierssen T, Vazquez-Rodriguez TR, Gomez-Acebo I, Blanco R, Gonzalez-Gay MA. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. <i>Medicine (Baltimore)</i> . 2011 Sep;90(5):350-358.
5	Alonso et al., 2011	2002-2006	Incidence (ACR)	Spain	Alonso MD, Llorca J, Martinez-Vazquez F, Miranda-Filloy JA, Diaz de Teran T, Dierssen T, Vazquez-Rodriguez TR, Gomez-Acebo I, Blanco R, Gonzalez-Gay MA. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. <i>Medicine (Baltimore)</i> . 2011 Sep;90(5):350-358.
106	López et al., 2003	2002	Incidence (ACR)	Spain	López P, Mozo L, Gutiérrez C, Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. <i>Lupus</i> . 2003;12(11):860-5.
53	Ingvarsson et al., 2016	1981-1993	Incidence (ACR)	Sweden	Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. <i>Lupus</i> . 2016 Jun;25(7):772-80.

53	Ingvarsson et al., 2016	1994-2006	Incidence (ACR)	Sweden	Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. <i>Lupus</i> . 2016 Jun;25(7):772-80.
104	Ståhl-Hallengren et al., 2000	1987-1991	Incidence (ACR)	Sweden	Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. <i>J Rheumatol</i> . 2000 Mar;27(3):685-91.
104	Ståhl-Hallengren et al., 2000	1981-1986	Incidence (ACR)	Sweden	Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. <i>J Rheumatol</i> . 2000 Mar;27(3):685-91.
76	Pamuk et al., 2016	2003-2014	Incidence (ACR)	Turkey	Pamuk ON, Balci MA, Donmez S, Tsokos GC. The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study. <i>Lupus</i> . 2016 Jan;25(1):102-9.
72	Nasonov et al., 2014	2010	Incidence (ACR)	Ukraine	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasylyev A, Pereira MH. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus</i> . 2014 Feb;23(2):213-9.
3	Al Dhanhani et al., 2017	2009-2012	Incidence (ACR)	United Arab Emirates	Al Dhanhani AM, Agarwal M, Othman YS, Bakoush O. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. <i>Lupus</i> . 2017 May;26(6):664-669.
51	Hopkinson et al., 1993	1989-1990	Incidence	United Kingdom	Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. <i>Br J Rheumatol</i> . 1993 Feb;32(2):110-5.
74	Nightingale et al., 2006	1992-1998	Incidence	United Kingdom	Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database. <i>Pharmacoepidemiol Drug Saf</i> . 2006 Sep;15(9):656-61.

78	Rees et al., 2016	1999	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2000	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2001	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2002	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2003	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2004	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2005	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2006	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2007	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.

78	Rees et al., 2016	2008	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2009	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2010	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2011	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2012	Incidence	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
84	Somers et al., 2007	1990-1999	Incidence	United Kingdom	Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. <i>Arthritis Rheum.</i> 2007 May 15;57(4):612-8.
64	Lythgoe et al., 2022	2017-2019	Incidence (ACR)	United Kingdom	Lythgoe H, Smith EMD, Killeen OG, Murphy R, Pilkington C, Pain CE, Beresford MW. Prospective epidemiological study of juvenile-onset Systemic Lupus Erythematosus in the United Kingdom and Republic of Ireland. <i>Rheumatology (Oxford).</i> 2022 Feb 3:keac064.
105	Johnson et al., 1995	1991	Incidence (ACR)	United Kingdom	Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. <i>Arthritis Rheum.</i> 1995 Apr;38(4):551-8.
39	Feldman et al., 2013	2000-2004	Incidence	United States	Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. <i>Arthritis Rheum.</i> 2013 Mar;65(3):753-63.

43	Furst et al., 2013	2003-2008	Incidence	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus</i> . 2013 Jan;22(1):99-105.
49	Hiraki et al., 2012	2000-2004	Incidence	United States	Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, Costenbader KH. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. <i>Arthritis Rheum</i> . 2012 Aug;64(8):2669-76.
93	Li et al., 2020	2009	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2010	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2011	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2012	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2013	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2014	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2015	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.

93	Li et al., 2020	2016	Incidence	United States	Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
17	Dall'Era et al., 2017	2007-2009	Incidence (ACR)	United States	Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis Rheumatol</i> . 2017 Oct;69(10):1996-2005.
41	Ferucci et al., 2014	2007-2009	Incidence (ACR)	United States	Ferucci ED, Johnston JM, Gaddy JR, Sumner L, Posever JO, Choromanski TL, Gordon C, Lim SS, Helmick CG. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. <i>Arthritis Rheumatol</i> . 2014 Sep;66(9):2494-502.
52	Housey et al., 2015	2002-2005	Incidence (ACR)	United States	Housey M, DeGuire P, Lyon-Calio S, Wang L, Marder W, McCune WJ, Helmick CG, Gordon C, Dhar JP, Leisen J, Somers EC. Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program. <i>Am J Public Health</i> . 2015 May;105(5):e74-9.
55	Izmirly et al., 2017	2007-2009	Incidence (ACR)	United States	Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Puttermann C, Gordon C, Helmick CG, Parton H. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis Rheumatol</i> . 2017 Oct;69(10):2006-2017.
56	Jarukitsopa et al., 2015	1993-2005	Incidence (ACR)	United States	Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, Matteson EL, Maradit Kremers H, Chowdhary VR. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. <i>Arthritis Care Res (Hoboken)</i> . 2015 May;67(6):817-28.
63	Lim et al., 2014	2002-2004	Incidence (ACR)	United States	Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. <i>Arthritis Rheumatol</i> . 2014 Feb;66(2):357-68.

68	McCarty et al., 1995	1985-1990	Incidence (ACR)	United States	McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. <i>Arthritis Rheum.</i> 1995 Sep;38(9):1260-70.
71	Naleway et al., 2005	1991-2001	Incidence (ACR)	United States	Naleway AL, Davis ME, Greenlee RT, Wilson DA, McCarty DJ. Epidemiology of systemic lupus erythematosus in rural Wisconsin. <i>Lupus.</i> 2005;14(10):862-6.
83	Somers et al., 2014	2002-2004	Incidence (ACR)	United States	Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. <i>Arthritis Rheumatol.</i> 2014 Feb;66(2):369-78.
86	Valenzuela-Almada et al., 2022	1976-2018	Incidence (ACR)	United States	Valenzuela-Almada MO, Hocaoglu M, Dabit JY, Osei-Onomah SA, Basiaga ML, Orandi AB, Giblon RE, Barbour KE, Crowson CS, Duarte-García A. Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. <i>Arthritis Care Res (Hoboken).</i> 2022 May;74(5):728-732.
92	Ungprasert et al., 2017	1993-2005	Incidence (ACR)	United States	Ungprasert P, Sagar V, Crowson CS, Amin S, Makol A, Ernste FC, Osborn TG, Moder KG, Niewold TB, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary VR. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. <i>Lupus.</i> 2017 Mar;26(3):240-247.
107	Uramoto et al., 1999	1980-1992	Incidence (ACR)	United States	Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. <i>Arthritis Rheum.</i> 1999 Jan;42(1):46-50.
92	Ungprasert et al., 2017	1993-2005	Incidence (SLICC)	United States	Ungprasert P, Sagar V, Crowson CS, Amin S, Makol A, Ernste FC, Osborn TG, Moder KG, Niewold TB, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary VR. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. <i>Lupus.</i> 2017 Mar;26(3):240-247.

Abbreviation: ACR, The American College of Rheumatology; ARA, The American Rheumatism Association; SLICC, The Systemic Lupus International Collaborating Clinics.

Table S7. Characteristics of studies reporting on prevalence of AD.

No.	Study	Study time	Prevalence type	Country	Reference
18	Quintana et al., 2016	2010	PT	Argentina	Quintana R, Silvestre AM, Goñi M, García V, Mathern N, Jorfen M, Miljevic J, Dhair D, Laithe M, Conti S, Midauar F, Martin MC, Barrios MC, Nieto R, Prigione C, Sanabria A, Gervasoni V, Grabbe E, Gontero R, Peláez-Ballestas I, Pons-Estel BA. Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina. <i>Clin Rheumatol</i> . 2016 Jul;35 Suppl 1(Suppl 1):5-14.
45	Gonzalez Lucero et al., 2020	2006	PP (1 year) (ACR)	Argentina	Gonzalez Lucero L, Barbaglia AL, Bellomio VI, Bertolaccini MC, Machado Escobar MA, Suello HR, Yacuzzi MS, Carrizo GA, Robles N, Rengel S, Cristofari A, Leal MO, Vasquez DL, Quinteros A, Seleme G, Molina MJ, Pera OL, Dip R, Olea AC, Torres AY, Espindola Echazu M, Arquez G, Lazaro H, Colombres F, Juarez LA, Romano O, Paz S, Santana M, Galindo L, Lucero E. Prevalence and incidence of systemic lupus erythematosus in Tucumán, Argentina. <i>Lupus</i> . 2020 Nov;29(13):1815-1820.
98	Scolnik et al., 2014	1998-2009	PT (ACR)	Argentina	Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS, Avellaneda NL, Etchepare A, Etchepare P, Plou MS, Soriano ER. Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. <i>Lupus Sci Med</i> . 2014 Jun 5;1(1):e000021.
100	Bossingham et al., 2003	1996-1998	PP (1 year) (ACR)	Australia	Bossingham D. Systemic lupus erythematosus in the far north of Queensland. <i>Lupus</i> . 2003;12(4):327-31.
101	Segasothy et al., 2001	1990-1999	PP (1 year) (ACR)	Australia	Segasothy M, Phillips PA. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study. <i>Lupus</i> . 2001;10(6):439-44.
111	Anstey et al., 1993	1991	PT (ARA)	Australia	Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. <i>Aust N Z J Med</i> . 1993 Dec;23(6):646-51.

42	Flower et al., 2012	2000-2009	PT (ACR)	Barbados	Flower C, Hennis AJ, Hambleton IR, Nicholson GD, Liang MH; Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. <i>Arthritis Care Res (Hoboken)</i> . 2012 Aug;64(8):1151-8.
19	Senna et al., 2004	NR	PT (ACR)	Brazil	Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM, Ferraz MB. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. <i>J Rheumatol</i> . 2004 Mar;31(3):594-7.
10	Bernatsky et al., 2007	1994-2003	PP (1 year)	Canada	Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE, Clarke AE. A population-based assessment of systemic lupus erythematosus incidence and prevalence--results and implications of using administrative data for epidemiological studies. <i>Rheumatology (Oxford)</i> . 2007 Dec;46(12):1814-8.
38	Fatoye et al., 2018	2000-2015	PP (1 year)	Canada	Fatoye F, Gebrye T, Svenson LW. Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada. <i>Rheumatol Int</i> . 2018 Sep;38(9):1721-1726.
73	Ng et al., 2013	2001	PP (1 year)	Canada	Ng R, Bernatsky S, Rahme E. Observation period effects on estimation of systemic lupus erythematosus incidence and prevalence in Quebec. <i>J Rheumatol</i> . 2013 Aug;40(8):1334-6.
77	Peschken et al., 2000	1996	PT (ACR)	Canada	Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. <i>J Rheumatol</i> . 2000 Aug;27(8):1884-91.
13	Chiu et al., 2010	2000	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2001	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2002	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2003	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2004	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.

13	Chiu et al., 2010	2005	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2006	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
13	Chiu et al., 2010	2007	PP (1 year)	China	Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. <i>Lupus</i> . 2010 Sep;19(10):1250-5.
20	Dai et al., 2003	1997-1998	PT (ACR)	China	Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. <i>J Rheumatol</i> . 2003 Oct;30(10):2245-51.
21	Wigley et al., 1994	NR	PT	China	Wigley RD, Zhang NZ, Zeng QY, Shi CS, Hu DW, Couchman K, Duff IF, Bennett PH. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. <i>J Rheumatol</i> . 1994 Aug;21(8):1484-90.
61	Leong et al., 2021	2001	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2002	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2003	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2004	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2005	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2006	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep</i> . 2021 Mar 11;11(1):5631.

61	Leong et al., 2021	2007	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2008	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2009	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2010	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
61	Leong et al., 2021	2011	PP (1 year)	China	Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. <i>Sci Rep.</i> 2021 Mar 11;11(1):5631.
99	Zou et al., 2014	2009-2010	PP (1 year) (ACR)	China	Zou YF, Feng CC, Zhu JM, Tao JH, Chen GM, Ye QL, Cen H, Leng RX, Pan FM, Pan HF, Li R, Fan YG, Wang B, Li XP, Zhang FY, Ye DQ. Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui Province. <i>Rheumatol Int.</i> 2014 Mar;34(3):347-56.
96	Zeng et al., 1994	NR	PT (ARA)	China	Zeng QY, Huang SB, Zhou XG, et al. Epidemiological investigation of rheumatism in the southern point of China-International Alliance against Rheumatism. <i>China Primary Medicine</i> , 1994(1):31-32.
11	Castro-Villarreal et al., 2021	2015-2017	PP (1 year)	Colombia	Castro-Villarreal S, Beltran-Ostos A, Valencia CF. Estimation of Prevalence and Incremental Costs of Systemic Lupus Erythematosus in a Middle-Income Country Using Machine Learning on Administrative Health Data. <i>Value Health Reg Issues.</i> 2021 Dec;26:98-104.
22	Francy-Milena Cuervo et al., 2020	2014-2016	PT (ACR)	Colombia	Francy-Milena Cuervo, Ana M. Santosa, Ingris Peláez-Ballesteras, et al. Comparison of quality of life in patients with musculoskeletal symptoms, those with other comorbidities, and healthy people, in a Colombian open population study. <i>rev colomb reumatol</i> . 2020;27(3):166-176

23	Londoño et al., 2018	2014-2016	PT (ACR)	Colombia	Londoño J, Peláez Ballestas I, Cuervo F, et al. Prevalence of rheumatic disease in Colombia according to the Colombian Rheumatology Association (COPCORD) strategy. Prevalence study of rheumatic disease in Colombian population older than 18 years. <i>Rev Colomb Reumatol.</i> 2018;25(4):245-256.
40	Fernández-Ávila et al., 2019	2012-2016	PP (1 year)	Colombia	Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez Dávila JM, Rosselli D. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012-2016. <i>Lupus.</i> 2019 Sep;28(10):1273-1278.
24	Llerena et al., 2000	1981	PT (ACR)	Cuba	Llerena GA, Toledo MG, Martínez AAH, et al. Prevalence of musculoskeletal complaints and disability in Cuba. A community based study using the COPCORD core questionnaire. <i>Clin Exp Rheumatol.</i> 2000;18:739-742.
109	Reyes-Llerena et al., 2009	NR	PT	Cuba	Reyes-Llerena GA, Guibert-Toledo M, Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R, Cardiel MH. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. <i>J Clin Rheumatol.</i> 2009 Mar;15(2):51-5.
48	Hermansen et al., 2016	2011	PT	Denmark	Hermansen ML, Lindhardsen J, Torp-Pedersen C, Faurschou M, Jacobsen S. Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. <i>J Rheumatol.</i> 2016 Jul;43(7):1335-9.
60	Lastrupup et al., 2009	1994	PT (ACR)	Denmark	Lastrupup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrupup et al., 2009	1995	PT (ACR)	Denmark	Lastrupup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrupup et al., 2009	1996	PT (ACR)	Denmark	Lastrupup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrupup et al., 2009	1997	PT (ACR)	Denmark	Lastrupup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.

60	Lastrup et al., 2009	1998	PT (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	1999	PT (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2000	PT (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2001	PT (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
60	Lastrup et al., 2009	2002	PT (ACR)	Denmark	Lastrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. <i>Scand J Rheumatol.</i> 2009 Mar-Apr;38(2):128-32.
103	Voss et al., 1998	1995	PT (ACR)	Denmark	Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. <i>Scand J Rheumatol.</i> 1998;27(2):98-105.
25	Guevara-Pacheco et al., 2016	2014	PT (ACR)	Ecuador	Guevara-Pacheco S, Feicán-Alvarado A, Sanín LH, et al. Prevalence of musculoskeletal disorders and rheumatic diseases in Cuenca, Ecuador: a WHO?ILAR COPCORD study. <i>Rheumatol Int.</i> 2016;36(9):1195-204.
75	Otsa et al., 2017	2006-2010	PT (ACR)	Estonia	Otsa K, Talli S, Harding P, Parsik E, Esko M, Teepere A, Tammaru M. Prevalence and incidence of systemic lupus erythematosus in the adult population of Estonia. <i>Lupus.</i> 2017 Sep;26(10):1115-1120.
6	Arnaud et al., 2014	2010	PP (1 year)	France	Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. <i>Autoimmun Rev.</i> 2014 Nov;13(11):1082-9.
36	Deligny et al., 2002	1999	PT (ACR)	France	Deligny C, Thomas L, Dubreuil F, Théodore C, Garsaud AM, Numéric P, Ranlin A, Jean-Baptiste G, Arfi S. Lupus systémique en Martinique: enquête

					épidémiologique [Systemic lupus erythematosus in Martinique: an epidemiologic study]. Rev Med Interne. 2002 Jan;23(1):21-9.
1	Brinks et al., 2014	2002	PP (1 year)	Germany	Brinks R, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M. Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. <i>Lupus</i> . 2014 Nov;23(13):1407-11.
2	Schwarting et al., 2021	2009	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2010	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2011	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2012	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2013	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
2	Schwarting et al., 2021	2014	PP (1 year)	Germany	Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. <i>Rheumatol Ther</i> . 2021 Mar;8(1):375-393.
94	Brinks et al., 2016	2002	PT	Germany	Brinks R, Hoyer A, Weber S, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M. Age-specific and sex-specific incidence of systemic lupus

					erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002. <i>Lupus Sci Med.</i> 2016 Nov 25;3(1):e000181.
4	Alamanos et al. 2003	2001	PT (ACR)	Greece	Alamanos Y, Voulgari PV, Siozos C, Katsimpi P, Tsintzos S, Dimou G, Politi EN, Rapti A, Laina G, Drosos AA. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. <i>J Rheumatol.</i> 2003 Apr;30(4):731-5.
44	Gergianaki et al., 2017	1999	PP (1 year) (ACR)	Greece	Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spiro G, Bertsias A, Kabouraki E, Tzanakis I, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias GK. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. <i>Ann Rheum Dis.</i> 2017 Dec;76(12):1992-2000.
44	Gergianaki et al., 2017	2013	PP (1 year) (ACR)	Greece	Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spiro G, Bertsias A, Kabouraki E, Tzanakis I, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias GK. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. <i>Ann Rheum Dis.</i> 2017 Dec;76(12):1992-2000.
97	Kedves et al., 2020	2010	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford).</i> 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2011	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford).</i> 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2012	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford).</i> 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2013	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated

					with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2014	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2015	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
97	Kedves et al., 2020	2016	PP (1 year)	Hungary	Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology (Oxford)</i> . 2020 Nov 1;59(11):3443-3451.
26	Chopra et al., 2015	2004-2010	PT	India	Chopra A. Disease burden of rheumatic diseases in India: COPCORD prospective. <i>Indian J Rheumatol</i> 2015;10:70-77.
66	Malaviya et al., 1993	1990	PT	India	Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. <i>Lupus</i> . 1993 Apr;2(2):115-8.
27	Davatchi et al., 2016	2004	PT	Iran	Davatchi F, Sandoughi M, Moghimi N, Jamshidi AR, Tehrani Banihashemi A, Zakeri Z, Sadeghi Abdollahi B. Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. <i>Int J Rheum Dis</i> . 2016 Nov;19(11):1056-1062.
28	Moghimi et al., 2015	2011-2012	PT	Iran	Moghimi N, Davatchi F, Rahimi E, Saidi A, Rashadmanesh N, Moghimi S, Ghafori H, Zandi P, Ahmadi N, Ghafori H, Moghimi M, hajiheshmati M. WHO-ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. <i>Clin Rheumatol</i> . 2015 Mar;34(3):535-43.
29	Sandoughi et al., 2013	2008-2009	PT (ACR)	Iran	Sandoughi M, Zakeri Z, Tehrani Banihashemi A, Davatchi F, Narouie B, Shikhzadeh A, Mohammadi M, Jahantigh M, Shakiba M, Moulaei NA, Yousefi S, Rezazehi B, Shirzaei Sani E, Emamdadi A, Hoseynian M, Masoodian S, Shahbakhsh S. Prevalence of musculoskeletal disorders in southeastern Iran: a

					WHO-ILAR COPCORD study (stage 1, urban study). <i>Int J Rheum Dis.</i> 2013 Oct;16(5):509-17.
30	Davatchi et al., 2009	2006	PT	Iran	Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M, Karimifar M, Essalatmanesh K, Barghamdi M, Noorolahzadeh E, Dahaghi S, Rasker JJ. The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. <i>Clin Rheumatol.</i> 2009 Nov;28(11):1267-74.
31	Davatchi et al., 2009	2004-2005	PT	Iran	Davatchi F, Jamshidi AR, Tehrani Banihashemi A, Gholami J, Hossein Forouzanfar M, Akhlaghi M, Barghamdi M, Noorolahzadeh E, Khabazi AR, Salesi M, Salari AH, Karimifar M, Essalat-Manesh K, Hajjaliloo M, Soroosh M, Farzad F, Moussavi HR, Samadi F, Ghaznavi K, Asgharifard H, Zangiabadi AH, Shahram F, Nadji A, Akbarian M, Gharibdoost F, Rasker JJ. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. <i>Clin Rheumatol.</i> 2009 Nov;28(11):1275-82.
9	Benuccci et al., 2005	2002	PT	Italy	Benuccci M, Del Rosso A, Li Gobbi F, Manfredi M, Cerinic MM, Salvarani C. Systemic lupus erythematosus (SLE) in Italy: an Italian prevalence study based on a two-step strategy in an area of Florence (Scandicci-Le Signe). <i>Med Sci Monit.</i> 2005 Sep;11(9):CR420-5.
47	Govoni et al., 2006	2002	PP (1 year) (ACR)	Italy	Govoni M, Castellino G, Bosi S, Napoli N, Trotta F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. <i>Lupus.</i> 2006;15(2):110-3.
85	Tsioni et al., 2015	2009-2012	PT (ACR)	Italy	Tsioni V, Andreoli L, Meini A, Frassi M, Raffetti E, Airò P, Allegri F, Donato F, Tincani A. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. <i>Clin Exp Rheumatol.</i> 2015 Sep-Oct;33(5):681-7.
54	Iseki et al., 1994	1982-1991	PP (1 year) (ARA)	Japan	Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. <i>Am J Kidney Dis.</i> 1994 Apr;23(4):547-54.
72	Nasonov et al., 2014	2010	PP (1 year) (ACR)	Kazakhstan	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasyliev A, Pereira MH. The prevalence and

					incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus</i> . 2014 Feb;23(2):213-9.
7	Bae et al., 2020	2005	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2006	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2007	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2008	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2009	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2010	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.
7	Bae et al., 2020	2011	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med</i> . 2020 May;35(3):652-661.

7	Bae et al., 2020	2012	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2013	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2014	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
7	Bae et al., 2020	2015	PP (1 year)	Korea	Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, Kim CS, Ma SK, Kim SW. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. <i>Korean J Intern Med.</i> 2020 May;35(3):652-661.
14	Chung et al., 2021	2009	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2010	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2011	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2012	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2013	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.

14	Chung et al., 2021	2014	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2015	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
14	Chung et al., 2021	2016	PP (1 year)	Korea	Chung MK, Park JS, Lim H, Lee CH, Lee J. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. <i>Lupus.</i> 2021 Apr;30(4):674-679.
57	Ju et al., 2014	2004-2006	PT (ACR)	Korea	Ju JH, Yoon SH, Kang KY, Kim IJ, Kwok SK, Park SH, Kim HY, Lee WC, Cho CS. Prevalence of systemic lupus erythematosus in South Korea: an administrative database study. <i>J Epidemiol.</i> 2014;24(4):295-303.
58	Kwak et al., 2021	2017	PP (1 year) (ACR)	Korea	Kwak SG, Park SH, Kim JY. Incidence and Prevalence of Juvenile Systemic Lupus Erythematosus in Korea: Data From the 2017 National Health Claims Database. <i>J Rheumatol.</i> 2021 Feb;48(2):258-261.
80	Shim et al., 2014	2006	PP (1 year) (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
80	Shim et al., 2014	2007	PP (1 year) (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
80	Shim et al., 2014	2008	PP (1 year) (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
80	Shim et al., 2014	2009	PP (1 year) (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
80	Shim et al., 2014	2010	PP (1 year) (ACR)	Korea	Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. <i>Rheumatol Int.</i> 2014 Jul;34(7):909-17.
16	Dadoniene et al., 2006	2004	PT (ACR)	Lithuania	Dadoniene J, Adomaviciute D, Rugiene R, Luksiene A, Venalis A. The prevalence of systemic lupus erythematosus in Lithuania: the lowest rate in Northern Europe. <i>Lupus.</i> 2006;15(8):544-6.

95	Magro et al., 2018	2012-2016	PT (SLICC)	Malta	Magro R, Borg AA. Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study. <i>Biomed Res Int.</i> 2018 Sep 30;2018:2385386.
32	Del Río Nájera et al., 2016	2014-2015	PT	Mexico	Del Río Nájera D, González-Chávez SA, Quiñonez-Flores CM, Peláez-Ballestas I, Hernández-Nájera N, Pacheco-Tena CF. Rheumatic Diseases in Chihuahua, México: A COPCORD Survey. <i>J Clin Rheumatol.</i> 2016 Jun;22(4):188-93.
33	Alvarez-Nemegyei et al., 2005 2011		PT (ACR)	Mexico	Alvarez-Nemegyei J, Peláez-Ballestas I, Sanin LH, Cardiel MH, Ramirez-Angulo A, Goycochea-Robles MV. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. <i>J Rheumatol Suppl.</i> 2011 Jan;86:21-5.
34	Peláez-Ballestas et al., 2005 2011		PT	Mexico	Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, Rodríguez-Amado J, Goycochea-Robles MV, Madariaga M, Zamudio J, Santana N, Cardiel MH; Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. <i>J Rheumatol Suppl.</i> 2011 Jan;86:3-8.
108	Nossent et al., 1992	1990	PT (ARA)	Netherlands	Nossent JC. Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation. <i>Ann Rheum Dis.</i> 1992 Nov;51(11):1197-201.
62	Lerang et al., 2012	2008	PT (ACR)	Norway	Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT. High incidence and prevalence of systemic lupus erythematosus in Norway. <i>Lupus.</i> 2012 Oct;21(12):1362-9.
102	Nossent et al., 2001	1978-1996	PT (ACR)	Norway	Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway. <i>J Rheumatol.</i> 2001 Mar;28(3):539-46.
69	Molina et al., 2007	2003	PP (1 year)	Puerto Rico	Molina MJ, Mayor AM, Franco AE, Morell CA, López MA, Vilá LM. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. <i>J Clin Rheumatol.</i> 2007 Aug;13(4):202-4.
72	Nasonov et al., 2014	2010	PP (1 year) (ACR)	Russia	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasylyev A, Pereira MH. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three

					Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus</i> . 2014 Feb;23(2):213-9.
110	Al-Arfaj et al., 2002	NR	PT (ACR)	Saudi Arabia	Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, Al-Saleh SS, Bahabri SA, Mousa MM, Sekeit MA. Prevalence of systemic lupus erythematosus in central Saudi Arabia. <i>Saudi Med J</i> . 2002 Jan;23(1):87-9.
5	Alonso et al., 2011	1987-1991	PT (ACR)	Spain	Alonso MD, Llorca J, Martinez-Vazquez F, Miranda-Filloy JA, Diaz de Teran T, Dierssen T, Vazquez-Rodriguez TR, Gomez-Acebo I, Blanco R, Gonzalez-Gay MA. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. <i>Medicine (Baltimore)</i> . 2011 Sep;90(5):350-358.
15	Cortés Verdú et al., 2020	2016-2017	PT (SLICC)	Spain	Cortés Verdú R, Pego-Reigosa JM, Seoane-Mato D, Morcillo Valle M, Palma Sánchez D, Moreno Martínez MJ, Mayor González M, Atxotegi Sáenz de Buruaga J, Urionagüena Onaindia I, Blanco Cáceres BA, Silva-Fernández L, Sivera F, Blanco FJ, Sánchez-Piedra C, Díaz-González F, Bustabad S; Working Group Proyecto EPISER2016. Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? <i>Rheumatology (Oxford)</i> . 2020 Sep 1;59(9):2556-2562.
106	López et al., 2003	1998-2002	PT (ACR)	Spain	López P, Mozo L, Gutiérrez C, Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. <i>Lupus</i> . 2003;12(11):860-5.
53	Ingvarsson et al., 2016	1993	PT (ACR)	Sweden	Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. <i>Lupus</i> . 2016 Jun;25(7):772-80.
53	Ingvarsson et al., 2016	2006	PT (ACR)	Sweden	Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. <i>Lupus</i> . 2016 Jun;25(7):772-80.
81	Simard et al., 2014	2010	PT	Sweden	Simard JF, Sjöwall C, Rönnblom L, Jönsen A, Svenungsson E. Systemic lupus erythematosus prevalence in Sweden in 2010: what do national registers say? <i>Arthritis Care Res (Hoboken)</i> . 2014 Nov;66(11):1710-7.
104	Ståhl-Hallengren et al., 2000	1986	PT (ACR)	Sweden	Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing

104	Ståhl-Hallengren et al., 2000	1991	PT (ACR)	Sweden	frequency of renal manifestations and good prognosis. <i>J Rheumatol.</i> 2000 Mar;27(3):685-91. Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. <i>J Rheumatol.</i> 2000 Mar;27(3):685-91.
76	Pamuk et al., 2016	2003-2014	PP (1 year) (ACR)	Turkey	Pamuk ON, Balci MA, Donmez S, Tsokos GC. The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study. <i>Lupus.</i> 2016 Jan;25(1):102-9.
76	Pamuk et al., 2016	2003-2014	PT (ACR)	Turkey	Pamuk ON, Balci MA, Donmez S, Tsokos GC. The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study. <i>Lupus.</i> 2016 Jan;25(1):102-9.
72	Nasonov et al., 2014	2010	PP (1 year) (ACR)	Ukraine	Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, Smailova Z, Chernogolov V, Malynovska K, Vasyliev A, Pereira MH. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). <i>Lupus.</i> 2014 Feb;23(2):213-9.
3	Al Dhanhani et al., 2017	2009-2012	PT (ACR)	United Arab Emirates	Al Dhanhani AM, Agarwal M, Othman YS, Bakoush O. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. <i>Lupus.</i> 2017 May;26(6):664-669.
46	Gourley et al., 1997	1993	PT	United Kingdom	Gourley IS, Patterson CC, Bell AL. The prevalence of systemic lupus erythematosus in Northern Ireland. <i>Lupus.</i> 1997;6(4):399-403.
51	Hopkinson et al., 1993	1989-1990	PP (1 year)	United Kingdom	Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. <i>Br J Rheumatol.</i> 1993 Feb;32(2):110-5.
78	Rees et al., 2016	1999	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.

78	Rees et al., 2016	2000	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2001	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2002	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2003	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2004	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2005	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2006	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2007	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2008	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2009	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.

78	Rees et al., 2016	2010	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2011	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
78	Rees et al., 2016	2012	PT	United Kingdom	Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. <i>Ann Rheum Dis.</i> 2016 Jan;75(1):136-41.
79	Samanta et al., 1992	1989	PT (ARA)	United Kingdom	Samanta A, Roy S, Feehally J, Symmons DP. The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK. <i>Br J Rheumatol.</i> 1992 Oct;31(10):679-82.
105	Johnson et al., 1995	1992	PT (ACR)	United Kingdom	Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. <i>Arthritis Rheum.</i> 1995 Apr;38(4):551-8.
8	Balluz et al., 2001	1997	PT (ACR)	United States	Balluz L, Philen R, Ortega L, Rosales C, Brock J, Barr D, Kieszak S. Investigation of systemic lupus erythematosus in Nogales, Arizona. <i>Am J Epidemiol.</i> 2001 Dec 1;154(11):1029-36.
12	Chakravarty et al., 2007	2000	PP (1 year)	United States	Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. <i>Arthritis Rheum.</i> 2007 Jun;56(6):2092-4.
17	Dall'Era et al., 2017	2007-2009	PP (1 year) (ACR)	United States	Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis Rheumatol.</i> 2017 Oct;69(10):1996-2005.
39	Feldman et al., 2013	2000-2004	LT	United States	Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. <i>Arthritis Rheum.</i> 2013 Mar;65(3):753-63.

41	Ferucci et al., 2014	2007	PP (1 year) (ACR)	United States	Ferucci ED, Johnston JM, Gaddy JR, Sumner L, Posever JO, Choromanski TL, Gordon C, Lim SS, Helmick CG. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. <i>Arthritis Rheumatol.</i> 2014 Sep;66(9):2494-502.
43	Furst et al., 2013	2003	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
43	Furst et al., 2013	2004	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
43	Furst et al., 2013	2005	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
43	Furst et al., 2013	2006	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
43	Furst et al., 2013	2007	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
43	Furst et al., 2013	2008	PP (1 year)	United States	Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus.</i> 2013 Jan;22(1):99-105.
49	Hiraki et al., 2012	2000-2004	PP (1 year)	United States	Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, Costenbader KH. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. <i>Arthritis Rheum.</i> 2012 Aug;64(8):2669-76.
50	Hochberg et al., 1995	NR	LT	United States	Hochberg MC, Perlmutter DL, Medsger TA, Steen V, Weisman MH, White B, Wigley FM. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. <i>Lupus.</i> 1995 Dec;4(6):454-6.

- 50 Hochberg et al., 1995 NR LT (ACR) United States Hochberg MC, Perlmutter DL, Medsger TA, Steen V, Weisman MH, White B, Wigley FM. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. *Lupus*. 1995 Dec;4(6):454-6.
- 52 Housey et al., 2015 2002-2005 PP (1 year) (ACR) United States Housey M, DeGuire P, Lyon-Calio S, Wang L, Marder W, McCune WJ, Helmick CG, Gordon C, Dhar JP, Leisen J, Somers EC. Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program. *Am J Public Health*. 2015 May;105(5):e74-9.
- 55 Izmirly et al., 2017 2007 PP (1 year) (ACR) United States Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Puterman C, Gordon C, Helmick CG, Parton H. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. *Arthritis Rheumatol*. 2017 Oct;69(10):2006-2017.
- 56 Jarukitsopa et al., 2015 2006 PT (ACR) United States Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, Matteson EL, Maradit Kremers H, Chowdhary VR. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. *Arthritis Care Res (Hoboken)*. 2015 May;67(6):817-28.
- 59 Lahita et al., 1995 NR LT United States Lahita RG. Special report: adjusted lupus prevalence. Results of a marketing study by the Lupus Foundation of America. *Lupus*. 1995 Dec;4(6):450-3.
- 63 Lim et al., 2014 2002 PP (1 year) (ACR) United States Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. *Arthritis Rheumatol*. 2014 Feb;66(2):357-68.
- 67 Maskarinec et al., 1995 1989 PP (1 year) (ARA) United States Maskarinec G, Katz AR. Prevalence of systemic lupus erythematosus in Hawaii: is there a difference between ethnic groups? *Hawaii Med J*. 1995 Feb;54(2):406-9.
- 71 Naleway et al., 2005 2001 PT (ACR) United States Naleway AL, Davis ME, Greenlee RT, Wilson DA, McCarty DJ. Epidemiology of systemic lupus erythematosus in rural Wisconsin. *Lupus*. 2005;14(10):862-6.
- 83 Somers et al., 2014 2002-2004 PP (1 year) (ACR) United States Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, Wing JJ, Dhar JP, Leisen J, Shaltis D, McCune WJ. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus

				Epidemiology and Surveillance program. <i>Arthritis Rheumatol.</i> 2014 Feb;66(2):369-78.
86	Valenzuela-Almada et al., 2015 2022	PT (ACR)	United States	Valenzuela-Almada MO, Hocaoglu M, Dabit JY, Osei-Onomah SA, Basiaga ML, Orandi AB, Giblon RE, Barbour KE, Crowson CS, Duarte-García A. Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. <i>Arthritis Care Res (Hoboken).</i> 2022 May;74(5):728-732.
88	Walsh et al., 2001	NR	LT (ACR)	United States Walsh BT, Pope C, Reid M, Gall EP, Yocom DE, Clark LC. SLE in a United States-Mexico border community. <i>J Clin Rheumatol.</i> 2001 Feb;7(1):3-9.
89	Wang et al., 2016	2016	PP (1 year)	United States Wang Y, Hester LL, Lofland J, Rose S, Karyekar CS, Kern DM, Blacketer M, Davis K, Shields-Tuttle K. Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. <i>BMC Res Notes.</i> 2022 Jan 9;15(1):5.
90	Ward et al., 2004	1988-1994	LT	United States Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. <i>J Womens Health (Larchmt).</i> 2004 Jul-Aug;13(6):713-8.
93	Li et al., 2020	2009	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus.</i> 2020 Jan;29(1):15-26.
93	Li et al., 2020	2010	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus.</i> 2020 Jan;29(1):15-26.
93	Li et al., 2020	2011	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus.</i> 2020 Jan;29(1):15-26.
93	Li et al., 2020	2012	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus.</i> 2020 Jan;29(1):15-26.
93	Li et al., 2020	2013	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus.</i> 2020 Jan;29(1):15-26.

93	Li et al., 2020	2014	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2015	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
93	Li et al., 2020	2016	PP (1 year)	United States Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. <i>Lupus</i> . 2020 Jan;29(1):15-26.
107	Uramoto et al., 1999	1993	PT (ACR)	United States Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. <i>Arthritis Rheum</i> . 1999 Jan;42(1):46-50.
35	Granados et al., 2015	2011	PT (ACR)	Venezuela Granados Y, Cedeño L, Rosillo C, Berbin S, Azocar M, Molina ME, Lara O, Sanchez G, Peláez-Ballestas I. Prevalence of musculoskeletal disorders and rheumatic diseases in an urban community in Monagas State, Venezuela: a COPCORD study. <i>Clin Rheumatol</i> . 2015 May;34(5):871-7.

Abbreviation: NR, not reported; ACR, The American College of Rheumatology; ARA, The American Rheumatism Association; SLICC, The Systemic Lupus International Collaborating Clinics.

Appendix 5 Quality assessment of studies using the AXIS tool

Table S8. Quality assessment of studies using the AXIS tool.

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
Al Dhanhani et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low	
Alamanos et al. 2003	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	N/A	Low	
Al-Arfaj et al., 2002	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	No	Unclear	Medium	
Alonso et al., 2011	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	N/A	Low	
Alvarez-Nemegyei et al., 2011	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	High	

Anstey et al., 1993	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Low	
Arnaud et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Bae et al., 2020	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Balluz et al., 2001	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Benucci et al., 2005	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Bernatsky et al., 2007	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Bossingham et al., 2003	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Brinks et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Brinks et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Castro-Villarreal et al., 2021	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Chakravarty et al., 2007	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Chiu et al., 2010	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	No	No	N/A	Yes	Yes	Yes	No	N/A	High	
Chopra et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Unclear	No	Yes	Yes	Yes	No	Unclear	High	
Chung et al., 2021	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Cortés Verdú et al., 2020	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Dadoniene et al., 2006	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	No	No	Yes	Yes	Yes	No	Yes	High	
Dai et al., 2003	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	High	
Dall'Era et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Davatchi et al., 2009	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Davatchi et al., 2009	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Davatchi et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Del Río Nájera et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Low	
Deligny et al., 2002	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Elfving et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Fatoye et al., 2018	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Feldman et al., 2013	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	
Fernández-Ávila et al., 2019	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	No	No	N/A	Yes	Yes	Yes	No	N/A	High	
Ferucci et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low	

Flower et al., 2012	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	Medium
Francy-Milena Cuervo et al., 2020	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Furst et al., 2013	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Gergianaki et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Gonzalez Lucero et al., 2020	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Gourley et al., 1997	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Unclear	Medium
Govoni et al., 2006	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Granados et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Low
Guevara-Pacheco et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Low
Hermansen et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	Yes	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Hiraki et al., 2012	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	No	N/A	Low
Hochberg et al., 1995	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	No	Yes	High
Hopkinson et al., 1993	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	High
Housey et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Ingvarsson et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Iseki et al., 1994	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Izmirly et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Jarukitsopa et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Johnson et al., 1995	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Low
Ju et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Kedves et al., 2020	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Kwak et al., 2021	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Lahita et al., 1995	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Unclear	No	Yes	Yes	Yes	Yes	No	Unclear	High
Lastrup et al., 2009	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Low
Leong et al., 2021	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Lerang et al., 2012	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Li et al., 2020	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low

	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Llerena et al., 2000	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Londoño et al., 2018	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
López et al., 2003	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Lythgoe et al., 2022	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Mackie et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	N/A	Low
Magro et al., 2018	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Low
Malaviya et al., 1993	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	Medium
Maskarinec et al., 1995	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	Medium
McCarty et al., 1995	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Moghimi et al., 2015	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Mok et al., 2008	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Molina et al., 2007	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Molokhia et al., 2001	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	High
Naleway et al., 2005	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Nasonov et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Ng et al., 2013	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	High
Nightingale et al., 2006	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	No	No	Yes	No	N/A	Yes	Yes	Yes	Yes	No	N/A	High
Nossent et al., 1992	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Nossent et al., 2001	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Otsa et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Pamuk et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Peláez-Ballestas et al., 2011	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Low
Peschken et al., 2000	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Quintana et al., 2016	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Rees et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Reyes-Llerena et al., 2009	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Samanta et al., 1992	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High

	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Sandoughi et al., 2013	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Schwarting et al., 2021	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	N/A	Yes	Yes	Yes	Yes	Yes	No	N/A	Low
Scolnik et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Segasothy et al., 2001	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Senna et al., 2004	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	No	Yes	High
Shim et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Simard et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Śliwczynski et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Somers et al., 2007	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Somers et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Ståhl-Hallengren et al., 2000	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Tsioni et al., 2015	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Ungprasert et al., 2017	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Uramoto et al., 1999	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Valenzuela-Almada et al., 2022	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Vilar et al., 2002	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Voss et al., 1998	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Walsh et al., 2001	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Wang et al., 2016	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Ward et al., 2004	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Wigley et al., 1994	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Yeh et al., 2013	Yes	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	No	N/A	Yes	Yes	Yes	Yes	No	N/A	Low
Zeng et al., 1994	Yes	Yes	No	Yes	Yes	Yes	N/A	Yes	Yes	Yes	Yes	No	Yes	N/A	Yes	Yes	Yes	No	No	Yes	High
Zou et al., 2014	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Low

AXIS: Appraisal tool of Cross-Sectional Studies:

Q1) Were the aims/objectives of the study clear?

Q2) Was the study design appropriate for the stated aim(s)?

- Q3) Was the sample size justified?
- Q4) Was the target/reference population clearly defined? (Is it clear who the research was about?)
- Q5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?
- Q6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation?
- Q7) Were measures undertaken to address and categorise non-responders?
- Q8) Were the risk factor and outcome variables measured appropriate to the aims of the study?
- Q9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published previously?
- Q10) Is it clear what was used to determine statistical significance and/or precision estimates? (eg, p values, CIs)
- Q11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?
- Q12) Were the basic data adequately described?
- Q13) Does the response rate raise concerns about non-response bias?
- Q14) If appropriate, was information about non-responders described?
- Q15) Were the results internally consistent?
- Q16) Were the results for the analyses described in the methods, presented?
- Q17) Were the authors' discussions and conclusions justified by the results?
- Q18) Were the limitations of the study discussed?
- Q19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?
- Q20) Was ethical approval or consent of participants attained?

Appendix 6 Countries and territories in analysis regions

Table S9. Countries and territories in analysis regions. The table gives the full details of the geographical groups and hierarchy used in the statistical model. The classification is the same as the one used by the Global Burden of Disease and by the United Nations. The hierarchy mainly follows geography and income.

Region	Countries
Central Europe, eastern Europe, and central Asia	
Asia, central	Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan
Europe, central	Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, TFYR Macedonia
Europe, eastern	Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, Ukraine
High income	
Asia Pacific, high income	Brunei Darussalam, Japan, Republic of Korea, Singapore
Australasia	Australia, New Zealand
Europe, western	Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom
Latin America, southern	Argentina, Chile, Uruguay
North America, high income	Canada, United States of America
Latin America and Caribbean	
Caribbean	Antigua and Barbuda, Bahamas, Barbados, Belize, Cuba, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Virgin Island (US)
Latin America, Andean	Bolivia, Ecuador, Peru
Latin America, central	Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela (Bolivarian Republic of)
Latin America, tropical	Brazil, Paraguay
North Africa and Middle East	
North Africa and the Middle East	Afghanistan, Algeria, Bahrain, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territory, Oman, Qatar, Saudi Arabia, Sudan, Syrian Arab Republic, Sudan, Tunisia, Turkey, United Arab Emirates, Yemen
South Asia	
Asia, south	Bangladesh, Bhutan, India, Nepal, Pakistan
South East Asia, east Asia, and Oceania	

Asia, east	China, Dem. People's Republic of Korea
Asia, South East	Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, Maldives, Mauritius, Myanmar, Philippines, Seychelles, Sri Lanka, Thailand, Timor-Leste, Vietnam
Oceania	Fiji, Guam, Kiribati, Marshall Islands, Micronesia (Fed. States of), Papua New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu
Sub-Saharan Africa	
Sub-Saharan Africa, central	Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon
Sub-Saharan Africa, eastern	Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, South Sudan, Uganda, United Republic of Tanzania, Zambia
Sub-Saharan Africa, southern	Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe
Sub-Saharan Africa, western	Benin, Burkina Faso, Côte d'Ivoire, Cameroon, Cape Verde, Chad, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, Togo

References:

- United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2017 revision. Vol II. Demographic Profiles, 2017.
- Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ*. 2020 May 28;369:m1590.

Appendix 7 Statistical methods for incidence and prevalence calculation

The prevalence of SLE in different region levels was fitted by a Bayesian hierarchical linear mixed model. In hierarchical model, the prevalence of SLE in one region were estimated based on study data both from the same region and from other regions.

The model applied binomial family, and log-transformation was used to transform prevalence to a linear response variable. To divide countries into several hierarchies, we map all countries to regions/super-regions by the Global Burden of Disease (GBD) classification. In this study, this classification arranged 39 countries into 15 regions which nested in 6 super-regions hierarchically (Table S9).


The statistical was implemented by brms package in R (version 4.0.5). This package is based on Stan and could estimate posterior distribution by Hamiltonian Markov Chain Monte Carlo method. Four chains were used, and the iteration number was set as 4000. Besides region, we have set another three predictor variables with fixed effects. The four fixed variables are age strata, type of prevalence, sex and reporting method (Incidence model does not include type of prevalence and reporting method). Additionally, the model used a student_t(3, 0, 2.5) prior for the intercept. We reported the prevalence estimate with 95% uncertainty intervals. United Nation population structure provide the size of population in different age strata, it was used to estimate the SLE population in different countries/regions/super-regions. Finally, we also assessed the models in total, the fit of each model was assessed by effective sample size, and trace plots. Please contact Dingyao Zhang for the code of model estimation.


For prevalence model:

```
model <- brm(count | trials(allcount) ~ 1 + (1 | superregion/region/country) + (1 | diagnosis) + (1 | typeofrate) + (1 | ages) + (1 | sex), data =  
datause, family = binomial, thin = 10, chains = 4, iter = 4000, cores = 4, control = list(adapt_delta = 0.995, max_treedepth=20))
```

For incidence model:

```
model <- brm(count | trials(allcount) ~ 1 + (1 | superregion/region/country) + (1 | ages) + (1 | sex), data = datause, family = binomial, thin = 10,  
chains = 4, iter = 4000, cores = 4, control = list(adapt_delta = 0.995, max_treedepth=20))
```

Appendix 8 Trace plots for covariates in the Bayesian multilevel model**Figure S2.** Trace plots for covariates in the Bayesian multilevel model showing 1000 posterior draws total across 5 parallel chains.



Note: Global intercept is for fixed effect; age strata is the category for age strata for the overall population, children, and adults; diagnosis method is the variable type of diagnostic method; prevalence type is the variable type of prevalence measure; sex is the category for all, male, and female.

Appendix 9 Subgroup analysis of classification criteria and diagnostic method

We first compared model data with data from countries that have conducted multiple epidemiological studies. We conducted meta-analyses to integrate epidemiologic data within the same country. Because meta-analyses can only analyze less heterogenous data, the period prevalence with the largest amount of data should be the best choice for the validation, and epidemiologic data obtained from only adult and children population was excluded to avoid potential bias. The United States, China, and the Republic of Korea all had more than 5 available data for the analysis. Detailed results have been listed in Table S10. Data generated by our model fitted well in the period prevalence range. As for meta-analysis, loosely data distribution could lead to high heterogeneity and may alter results to deviate from the true value. Overall, the Republic of Korea yielded similar results to our model, while the meta-analysis results of the United States and China were higher than estimations generated by our model. Since the Bayesian model considers more information (like age strata and studies using other diagnosis method in those countries) than meta-analysis, this comparison strongly supported the accuracy of our model. Notably, since the prevalence of adults was much higher than that of children and most studies investigating the overall population (different age strata combined) focus only on adolescents and adults, the uneven age distribution made meta-analysis less representative. Our model normalizes the data to the natural age strata and therefore includes more children population, which may result in lower prevalence. Considering the constraints of age strata, the results generated by our model are not significantly different from those of the meta-analysis.

Table S10. Period prevalence for countries with more than 5 available data using different analytical methods.

Country	Period prevalence (1 year)	Period prevalence (1 year) (95% confidence intervals)	
		Range	Meta-analysis
The United States	9.7-241.9	71.42 (48.47-105.22)	53.9 (53.17-54.6)
China	1.8-81.1	57.79 (52.93-63.10)	47.53 (47.15-47.96)
Republic of Korea	6.9-79.5	26.28 (24.35-28.36)	26.29 (26.13-26.47)

*All prevalence data were normalized to rate per 100,000 persons.

Then we validated the model by comparing predicated number to actual number

of SLE patients. We used epidemiologic data from countries with more than 15 studies to make predictions about SLE patients. We included the relevant information such as country, region, prevalence or incidence, diagnostic method, age, sex, and number of investigated populations back into our Bayesian model to predict the number of SLE patients in each study and their 95% confidence interval (represented by red dots and lines in the graphs below). Green dots represent the actual number of SLE patients in each study.

In the incidence studies, the actual number of patients is similar to the predicted number. The predicted number of patients well balances the large discriminations in incidence between different studies conducted in the same country, suggesting that the incidence model fits well and can accurately integrate loose data to calculate incidence rates across countries.



Figure S3. Compare the predicted number of SLE patients using our model with the actual number of SLE patients in incidence studies.

In the prevalence studies, at the level of individual study, there was a certain gap between some predicted SLE patients and actual patients due to unignorable discriminations between studies conducted in the same country. However, it should be

acceptable since even two studies conducted under the same conditions in the same country could hold differences. Additionally, at the country level, our model can still well balance various studies and obtain relatively reasonable predictions of SLE patients, which shows that the prevalence model fits well and can accurately integrate loose data to calculate prevalence rates across countries. Overall, two different validation methods demonstrate the strength of our model. Based on these results, we believe that the model estimation is accurate, reliable and can represent the real-world situation.




Figure S4. Compare the predicted number of SLE patients using our model with the actual number of SLE patients in prevalence studies.

Appendix 10 Validate the accuracy of the Bayesian model

In our study, we included a total of 112 studies, 12 only reported SLE incidence, 46 reported SLE prevalence only, and 54 reported both SLE prevalence and incidence. Of all 66 studies reporting incidence, 43 mentioned SLE classification criteria, 41 used the ACR criteria, only 2 used SLICC criteria, and none of them used EULAR/ACR. Besides, of all 100 studies reporting prevalence, 58 mentioned SLE classification criteria, 57 used ACR criteria, only 1 used SLICC criteria, and none of the study used EULAR/ACR. Given that, we plan to estimate the impact of classification criteria on the epidemiology of SLE by comparing epidemiological data when only using the ACR classification criteria to those without classification criteria limitation. We calculated the SLE incidence and prevalence diagnosed according to the ACR classification criteria. The global SLE incidence and newly diagnosed population according to the ACR classification criteria were estimated to be 4.78 (1.46-12.11) per 100,000 person-years and 0.37 million people annually, which were slightly less than the estimations with no classification criteria limitations (5.14 (1.4-15.13) per 100,000 person-years and 0.40 million people annually). The global SLE prevalence and affected population according to the ACR classification criteria were estimated to be 50.80 (17.64-117.05) per 100,000 person-years and 3.96 million people, which were slightly higher than the estimations with no classification criteria limitation (43.7 (15.87-108.92) per 100,000 person-years and 3.41 million people). The ACR classification criteria did not significantly alter the estimated global incidence and prevalence, but different SLE diagnostic classification criteria may induce potential bias.




Figure S5. (A) SLE incidence according to ACR classification criteria for overall population according to world regions; (B) SLE incidence with no classification criteria limitation for overall population according to world regions; (C) SLE prevalence according to ACR classification criteria for overall population according to world regions; (D) SLE prevalence with no classification criteria limitation for overall population according to world regions.

In our study, self-reported diagnosis was defined as a patient reported that he or she had been diagnosed with SLE by a dermatologist or physician before, but no relevant medical record was provided. Self-reported diagnosis is mainly used when investigating lifetime prevalence or when having questionnaire-based survey, which often relies on patient recall due to the difficulty in integrating patients' clinical data. In our study, only 3 studies reported lifetime prevalence using self-reported diagnosis,

and in view of this, diagnostic methods only affected prevalence data. Our model estimated global SLE prevalence and affected population excluding self-reported diagnoses, as 44.12 (14.75-99.91) per 100,000 person-years and 3.44 million people, respectively, which were slightly higher than the estimations including all diagnostic methods (43.7 (15.87-108.92) per 100,000 person-years and 3.41 million people) (Figure 2). Overall, self-reported diagnosis in our study was based on the physician's former diagnosis rather than the patient's self-judgment, the major driver of this reporting error appears to be recall bias or being unaware of the diagnosis. Combined with the fact that the model only included 3 self-reported studies, and the model estimation showed these self-reported studies had little effect on global prevalence, we speculate that in our study, differences in diagnostic methods would not introduce much bias.




Figure S6. (A) SLE prevalence excluding self-reported diagnosis for overall population according to world regions. (B) SLE prevalence including all diagnostic methods for overall population according to world regions.